RespirCare A1 Smart Handheld Spirometer Receives CFDA Approval, Empowering Early COPD Diagnosis in Primary Care
At the 2017 Annual Conference of the Chinese Thoracic Society, held in Fuzhou on September 23, Huxijia joined forces with Zemy Technology (Beijing Zemy Technology Co., Ltd.) to host a satellite symposium themed “Application of Simplified Pulmonary Function Testing in Primary Care Hospitals.” The meeting invited Academician Zhong Nanshan as the Conference Chair and Professor Zhou Xin as the Keynote Speaker, leading discussions on how to promote and assist primary care hospitals in achieving wider adoption of pulmonary function testing more quickly and effectively.
Conference Chair: Academician Zhong Nanshan
Professor of Respiratory Medicine, Former President of the Chinese Medical Association, Honorary Director of the Guangzhou Institute of Respiratory Diseases, and Director of the National Clinical Research Center for Respiratory Diseases.
Academician Zhong Nanshan
Conference Speaker: Professor Zhou Xin
Department of Respiratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University; Vice Chairperson of the Respiratory Branch of the Chinese Medical Association; Leader of the Asthma Group, Respiratory Branch of the Chinese Medical Association.
Left: Professor Zhou Xin introduces the Huxijia A1
In his opening remarks at the conference, Academician Zhong Nanshan highlighted the Tie-COPD study recently published by the Guangzhou Institute of Respiratory Health team in The New England Journal of Medicine. The study results demonstrated that continuous pharmacological intervention for patients with early-stage chronic obstructive pulmonary disease (COPD) identified through early screening and diagnosis significantly improves patient symptoms and lung function. Therefore, it is essential to shift the paradigm of COPD diagnosis and treatment toward “early diagnosis and early treatment.”
Academician Zhong specifically pointed out: “My dream is to make lung function testing as simple as blood pressure measurement. I initially thought it would take ten years of effort to realize this dream, but it now appears that it will not take that long.” The Huxijia smart handheld spirometer is a product well-suited for promoting COPD screening at the primary care and community levels. I am pleased that Huxijia has entered the field of chronic respiratory disease management in China, jointly advancing the diagnosis and management of respiratory airway diseases in the country.
Professor Zhou Xin delivered a detailed report on the promotion and application of simplified pulmonary function testing in primary care hospitals. The report highlighted that among diagnosed COPD patients, only one-third were identified through pulmonary function testing, and 85% experienced a diagnostic delay of at least five years. Studies have shown that COPD patients experience rapid decline in lung function during the early stages of the disease; early screening and intervention can reduce the rate of acute exacerbations and slow the progression of lung function decline. Therefore, COPD requires early screening, early diagnosis, early intervention, and continuous management.
However, the nationwide prevalence of pulmonary function testing in China remains considerably low, with even fewer primary care hospitals offering such services. Professor Zhou Xin pointed out that the high cost of large-scale pulmonary function devices used in clinical settings, along with their stringent requirements for working environments and operators, are the primary reasons why these devices cannot be widely deployed in primary care hospitals.
The Huxijia A1 is a pulmonary ventilation testing device better suited for primary care hospitals. First, its design is exceptionally compact and elegant; at first glance, it resembles a smartphone. No foreign competitors have managed to create such a small smart handheld spirometer, making this product a source of pride for China. Second, its measurement parameters include key indicators of ventilatory function—such as PEF, FEV1, and FVC—as well as markers for small airway function. Third, it features data recording capabilities that allow each test result to be uploaded to a mobile phone for dynamic monitoring of lung function. If patients are unable to interpret the results, the data can be synchronized with the physician’s system, enabling doctors to assess disease control based on the patient’s longitudinal lung function data.
Finally, the measurement accuracy and repeatability are excellent. Comparative trials conducted at the Guangzhou Institute of Respiratory Health demonstrated that the Huxijia pulmonary function tester exhibits superior consistency in test results compared to large-scale spirometers used in hospitals.
After the conference, Academician Zhong spoke highly of the RespiHome smart handheld spirometer and provided insights into the future direction of pulmonary function testing.
About Breathing Home A1
The Huxijia A1 is the internationally leading and first smart handheld pulmonary function testing device independently developed by Huxijia over five years. Designed for individuals with respiratory diseases, it enables on-demand measurement and recording of pulmonary ventilation parameters (including PEF, FEV1, FVC, and small airway indicators such as MEF), with data synchronized to both patient and physician platforms. The system generates clear charts, simplified pulmonary (ventilation) function reports, and dynamic trend reports of ventilatory function. It is suitable for various clinical scenarios, including pulmonary function screening for patients with chronic obstructive pulmonary disease (COPD) and daily disease monitoring for asthma patients.
The Huxijia Smart Handheld Spirometer has obtained CFDA and CE certifications, holds 16 patents, and features a calibration procedure recognized by the medical community. Its measurement accuracy and repeatability both exceed industry standards. Huxijia will also leverage this device to support primary pulmonary function screening in China.
Huxijia is the first enterprise in China to enter the field of chronic respiratory disease management and has remained at the forefront of exploration. Upholding a patient-centered culture and driven by its mission to “enable everyone to breathe smoothly,” Huxijia is committed to making pulmonary function testing convenient, rapid, and accessible anytime, anywhere for both patients with chronic respiratory diseases and the general public. Through this conference, we will work more actively alongside national respiratory experts to advance the management of chronic respiratory diseases in China, particularly by promoting the widespread adoption of pulmonary function testing at the primary care level.